STAT3 and hepatocellular carcinoma: In addition, sorafenib-mediated upregulation of STAT3 in HCC cells contributes to sorafenib resistance,24 and combination treatment with a STAT3 inhibitor and sorafenib synergistically increases the antitumor effect of sorafenib on HCC cells.25